Beijing SL Pharmaceutical Co Ltd (002038) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beijing SL Pharmaceutical Co Ltd (002038) has a cash flow conversion efficiency ratio of -0.003x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-16.39 Million ≈ $-2.40 Million USD) by net assets (CN¥5.70 Billion ≈ $834.28 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Beijing SL Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how Beijing SL Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 002038 total debt and obligations for a breakdown of total debt and financial obligations.
Beijing SL Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beijing SL Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Brookline Bancorp Inc
NASDAQ:BRKL
|
0.027x |
|
Qisda Corp
TW:2352
|
0.051x |
|
Triveni Engineering & Industries Limited
NSE:TRIVENI
|
0.012x |
|
Biotest Aktiengesellschaft
XETRA:BIO
|
-0.114x |
|
Longyan Zhuoyue New Energy Co Ltd
SHG:688196
|
0.135x |
|
Fujian Apex Software Co Ltd
SHG:603383
|
-0.024x |
|
Everlight Chemical Industrial Corp
TW:1711
|
0.045x |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
0.039x |
Annual Cash Flow Conversion Efficiency for Beijing SL Pharmaceutical Co Ltd (2003–2024)
The table below shows the annual cash flow conversion efficiency of Beijing SL Pharmaceutical Co Ltd from 2003 to 2024. For the full company profile with market capitalisation and key ratios, see 002038 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥5.58 Billion ≈ $816.62 Million |
CN¥225.49 Million ≈ $33.00 Million |
0.040x | -48.99% |
| 2023-12-31 | CN¥5.81 Billion ≈ $850.19 Million |
CN¥460.20 Million ≈ $67.34 Million |
0.079x | +11.33% |
| 2022-12-31 | CN¥5.48 Billion ≈ $801.78 Million |
CN¥389.82 Million ≈ $57.04 Million |
0.071x | -18.44% |
| 2021-12-31 | CN¥5.33 Billion ≈ $779.39 Million |
CN¥464.63 Million ≈ $67.99 Million |
0.087x | +4.57% |
| 2020-12-31 | CN¥4.98 Billion ≈ $729.42 Million |
CN¥415.84 Million ≈ $60.85 Million |
0.083x | -39.59% |
| 2019-12-31 | CN¥4.82 Billion ≈ $705.49 Million |
CN¥665.83 Million ≈ $97.43 Million |
0.138x | +28.62% |
| 2018-12-31 | CN¥4.52 Billion ≈ $661.20 Million |
CN¥485.17 Million ≈ $71.00 Million |
0.107x | +21.25% |
| 2017-12-31 | CN¥4.30 Billion ≈ $629.14 Million |
CN¥380.72 Million ≈ $55.71 Million |
0.089x | -12.31% |
| 2016-12-31 | CN¥3.93 Billion ≈ $575.09 Million |
CN¥396.86 Million ≈ $58.07 Million |
0.101x | -27.73% |
| 2015-12-31 | CN¥3.61 Billion ≈ $528.73 Million |
CN¥504.87 Million ≈ $73.88 Million |
0.140x | -4.41% |
| 2014-12-31 | CN¥3.18 Billion ≈ $465.50 Million |
CN¥465.00 Million ≈ $68.04 Million |
0.146x | +8.93% |
| 2013-12-31 | CN¥2.59 Billion ≈ $378.85 Million |
CN¥347.41 Million ≈ $50.84 Million |
0.134x | -28.91% |
| 2012-12-31 | CN¥2.11 Billion ≈ $308.98 Million |
CN¥398.60 Million ≈ $58.33 Million |
0.189x | +39.20% |
| 2011-12-31 | CN¥1.69 Billion ≈ $246.66 Million |
CN¥228.59 Million ≈ $33.45 Million |
0.136x | -31.02% |
| 2010-12-31 | CN¥1.21 Billion ≈ $177.26 Million |
CN¥238.13 Million ≈ $34.85 Million |
0.197x | +10.81% |
| 2009-12-31 | CN¥983.06 Million ≈ $143.85 Million |
CN¥174.41 Million ≈ $25.52 Million |
0.177x | -30.38% |
| 2008-12-31 | CN¥762.61 Million ≈ $111.59 Million |
CN¥194.32 Million ≈ $28.44 Million |
0.255x | +59.16% |
| 2007-12-31 | CN¥551.93 Million ≈ $80.76 Million |
CN¥88.36 Million ≈ $12.93 Million |
0.160x | +18.56% |
| 2006-12-31 | CN¥426.20 Million ≈ $62.37 Million |
CN¥57.55 Million ≈ $8.42 Million |
0.135x | +8.78% |
| 2005-12-31 | CN¥382.49 Million ≈ $55.97 Million |
CN¥47.48 Million ≈ $6.95 Million |
0.124x | +43.52% |
| 2004-12-31 | CN¥361.45 Million ≈ $52.89 Million |
CN¥31.26 Million ≈ $4.57 Million |
0.086x | -67.43% |
| 2003-12-31 | CN¥115.05 Million ≈ $16.84 Million |
CN¥30.55 Million ≈ $4.47 Million |
0.266x | -- |
About Beijing SL Pharmaceutical Co Ltd
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People's Republic of China and internationally. The company's finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; pegylated human granulocyte-stimulating factor injection; human granulocyte-cell stimulating factor injecti… Read more